参考文献/References:
[1].Ponikowski P,Voors AA,Anker SD,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC) developed with the special contribution of the Heart Failure Association(HFA) of the ESC[J]. Eur Heart J,2016,37(27):2129-2200.
[2].Sarhene M,Wang Y,Wei J,et al. Biomarkers in heart failure:the past,current and future[J]. Heart Fail Rev,2019,24(6):867-903.
[3].Troughton R,Michael Felker G,Januzzi JL Jr. Natriuretic peptide-guided heart failure management[J]. Eur Heart J,2014,35(1):16-24.
[4].R?rth R,Jhund PS,Yilmaz MB,et al. Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction[J]. Circ Heart Fail,2020,13(2):e006541.
[5].Sbolli M,deFilippi C. BNP and NT-proBNP interpretation in the neprilysin inhibitor era[J]. Curr Cardiol Rep,2020,22(11):150.
[6].Rapatz K,Finsterer J,Voill-Glaninger A,et al. NT-pro-BNP in patients with left ventricular hypertrabeculation/non-compaction[J]. ESC Heart Fail,2020,7(6):4126-4133.
[7].Reginauld SH,Sangaralingham SJ,Iyer SR,et al. ANP production is impaired in acute decompensated heart failure[J]. J Card Fail,2020,26(10):s19.
[8].Davidovski FS,Goetze JP. ProANP and proBNP in plasma as biomarkers of heart failure[J]. Biomark Med,2019,13(13):1129-1135.
[9].Kriechbaum SD,Wiedenroth CB,Peters K,et al. Galectin-3,GDF-15,and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension[J]. Biomarkers,2020,25(7):578-586.
[10].Homsak E,Gruson D. Soluble ST2:a complex and diverse role in several diseases[J]. Clin Chim Acta,2020,507:75-87.
[11].Song Y,Li F,Xu Y,et al. Prognostic value of sST2 in patients with heart failure with reduced,mid-range and preserved ejection fraction[J]. Int J Cardiol,2020,304:95-100.
[12].Pourafkari L,Tajlil A,Nader ND,et al. Biomarkers in diagnosing and treatment of acute heart failure[J]. Biomark Med,2019,13(14):1235-1249.
[13].Kanukurti J,Mohammed N,Sreedevi NN,et al. Evaluation of galectin-3 as a novel diagnostic biomarker in patients with heart failure with preserved ejection fraction[J]. J Lab Physicians,2020,12(2):126-132.
[14].Komici K,Gnemmi I,Bencivenga L,et al. Impact of galectin-3 circulating levels on frailty in elderly patients with systolic heart failure[J]. J Clin Med,2020,9(7):2229.
[15].Wang N,Dang M,Zhang W,et al.Galectin-3 is associated with severe heart failure and death:a hospital-based study in Chinese patients[J]. Scand J Immunol,2020,91(5):e12826.
[16].Chen H,Chen C,Fang J,et al. Circulating galectin-3 on admission and prognosis in acute heart failure patients:a meta-analysis[J]. Heart Fail Rev,2020,25(2):331-341.
[17].Krebber MM,van Dijk CGM,Vernooij RWM,et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in extracellular matrix remodeling during left ventricular diastolic dysfunction and heart failure with preserved ejection fraction:a systematic review and meta-analysis[J]. Int J Mol Sci,2020,21(18):6742.
[18].Suthahar N,Meems LMG,Ho JE,et al. Sex-related differences in contemporary biomarkers for heart failure:a review[J]. Eur J Heart Fail,2020,22(5):775-788.
[19].Jordakieva G,Budge-Wolfram RM,Budinsky AC,et al. Plasma MMP-9 and TIMP-1 levels on ICU admission are associated with 30-day survival[J]. Wien Klin Wochenschr,2021,133(3-4):86-95.
[20].Manka SW,Bihan D,Farndale RW. Structural studies of the MMP-3 interaction with triple-helical collagen introduce new roles for the enzyme in tissue remodelling[J]. Sci Rep,2019,9(1):18785.
[21].Lijnen PJ,Maharani T,Finahari N,et al. Serum collagen markers and heart failure[J]. Cardiovasc Haematol Disord Drug Targets,2012,12(1):51-55.
[22].Kociol RD,Pang PS,Gheorghiade M,et al. Troponin elevation in heart failure[J]. J Am Coll Cardiol,2010,56(14):1071-1078.
[23].Tang O,Matsushita K,Coresh J,et al. High-sensitivity cardiac troponin I and T for cardiovascular risk stratification in adults with diabetes[J]. Diabetes Care,2020,43(10):e144-e146.
[24].Yan I,B?rschel CS,Neumann JT,et al. High-sensitivity cardiac troponin I levels and prediction of heart failure:results from the BiomarCaRE consortium[J]. JACC Heart Fail,2020,8(5):401-411.
[25].Coldren WH,Tikunova SB,Davis JP,et al. Discovery of novel small-molecule calcium sensitizers for cardiac troponin C:a combined virtual and experimental screening approach[J]. J Chem Inf Model,2020,60(7):3648-3661.
[26].Goel H,Melot J,Krinock MD,et al. Heart-type fatty acid-binding protein an overlooked cardiac biomarker[J]. Ann Med,2020,52(8):444-461.
[27].Otaki Y,Watanabe T,Kubota I. Heart-type fatty acid-binding protein in cardiovascular disease:a systemic review[J]. Clin Chim Acta,2017,474:44-53.
[28].[28] Lakhani I,Wong MV,Hung JKF,et al. Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction:a systematic review and meta-analysis[J]. Heart Fail Rev,2020 Feb 6.DOI: 10.1007/s10741-020-09927-x.?Online ahead of print.
[29].[29] Sabbah MS,Fayyaz AU,de Denus S,et al. Obese-inflammatory phenotypes in heart failure with preserved ejection fraction[J]. Circ Heart Fail,2020,13(8):e006414.
[30].[30] DuBrock HM,AbouEzzeddine OF,Redfield MM. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction[J]. PLoS One,2018,13(8):e0201836.
[31].[31] Hanna A,Frangogiannis NG. Inflammatory cytokines and chemokines as therapeutic targets in heart failure[J]. Cardiovasc Drugs Ther,2020,34(6):849-863.
[32].[32] Warbrick I,Rabkin SW. Hypoxia-inducible factor 1-alpha (HIF-1α) as a factor mediating the relationship between obesity and heart failure with preserved ejection fraction[J]. Obes Rev,2019,20(5):701-712.
[33].[33] Jin Y,Kong D,Liu C,et al. Role of IL-33 in transplant biology[J]. Eur Cytokine Netw,2019,30(2):39-42.
[34].[34] Ghali R,Altara R,Louch WE,et al. IL-33(interleukin 33)/sST2 axis in hypertension and heart failure[J]. Hypertension,2018,72(4):818-828.
[35].[35] Arfsten H,Cho A,Freitag C,et al. GDF-15 in solid vs non-solid treatment-na?ve malignancies[J]. Eur J Clin Invest,2019,49(11):e13168.
[36].[36] Bettencourt P,Ferreira-Coimbra J,Rodrigues P,et al. Towards a multi-marker prognostic strategy in acute heart failure:a role for GDF-15[J]. ESC Heart Fail,2018,5(6):1017-1022.
[37].[37] Jirak P,Pistulli R,Lichtenauer M,et al. Expression of the novel cardiac biomarkers sST2,GDF-15,suPAR,and H-FABP in HFpEF patients compared to ICM,DCM,and controls[J]. J Clin Med,2020,9(4):1130.
[38].[38] Chaikijurajai T,Tang WHW. Reappraisal of inflammatory biomarkers in heart failure[J]. Curr Heart Fail Rep,2020,17(1):9-19.
[39].[39] Medvedeva EA,Berezin II,Shchukin YV,et al. Galectin-3,markers of oxidative stress and renal dysfunction in patients with chronic heart failure[J]. Kardiologiia,2017,57(3):46-50.
[40].[40] Li M,Duan L,Li Y,et al. Long noncoding RNA/circular noncoding RNA-miRNA-mRNA axes in cardiovascular diseases[J]. Life Sci,2019,233:116440.
[41].[41] Cruz MS,da Silva AMG,de Souza KSC,et al. miRNAs emerge as circulating biomarkers of post-myocardial infarction heart failure[J]. Heart Fail Rev,2020,25(2):321-329.
[42].[42] Sygitowicz G,Maciejak-Jastrz?bska A,Sitkiewicz D. MicroRNAs in the?development of left ventricular remodeling and postmyocardial infarction heart failure[J]. Pol Arch Intern Med,2020,130(1):59-65.
[43].[43] Wang Y,Liang Y,Zhao W,et al. Circulating miRNA-21 as a diagnostic biomarker in elderly patients with type 2 cardiorenal syndrome[J]. Sci Rep,2020,10(1):4894.
相似文献/References:
[1]郭君君,郑宏超,曹阳.生物标志物对急性心肌梗死介入治疗预后的预测意义[J].心血管病学进展,2016,(1):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
GUO Junjun,ZHENG Hongchao,CAO Yang.Prognostic Significance of Biomarkers in Predicting Acute Myocardial
Infarction after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2016,(7):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
[2]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(7):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[3]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(7):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[4]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(7):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[5]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(7):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[6]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(7):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[7]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(7):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[8]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(7):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[9]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[10]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(7):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[11]刘壮壮 黄宇理.心力衰竭生物标志物的研究进展[J].心血管病学进展,2020,(1):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
LIU Zhuangzhuang,HUANG Yuli.Biomarkers for Heart Failure[J].Advances in Cardiovascular Diseases,2020,(7):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
[12]王同霞 陈章荣.可溶ST2与心力衰竭患者预后的评价[J].心血管病学进展,2020,(5):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
WANG Tongxia,CHEN Zhangrong.Prognosis of Heart Failure Patients and Soluble ST2[J].Advances in Cardiovascular Diseases,2020,(7):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
[13]孙悦宁 富路.左心室逆重构在心力衰竭中的研究新进展[J].心血管病学进展,2021,(6):525.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.012]
SUN Yuening,FU Lu.Research Progress of Left Ventricular Reverse Remodeling in Heart Failure[J].Advances in Cardiovascular Diseases,2021,(7):525.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.012]